Dr. Martina RossiPhDBPC-157 is a synthetic pentadecapeptide described in the originating literature as a partial sequence of a protective protein reported in human gastric juice, investigated in preclinical models for its potential effects on tissue repair, tendon healing, and angiogenesis. Animal research has examined tendon, ligament, and muscle tissue healing following injury, with findings suggesting accelerated repair responses in preclinical models. Nearly all published research is preclinical: a 2025 systematic review of the orthopedic literature identified 36 studies, of which 35 were preclinical and only one clinical (a retrospective case series of 12 patients). No randomized controlled trial has validated these effects in humans.
Research on BPC-157 has grown steadily over the past three decades, drawing interest from groups studying tissue repair, angiogenesis, and connective tissue biology. BPC-157 is a synthetic peptide investigated in laboratory and animal models, and the published literature on tissue repair is almost entirely preclinical. This article summarizes what the body of BPC-157 research shows about tendon, ligament, and muscle repair in experimental settings, the mechanisms researchers have proposed, and the areas where evidence remains limited. It is written for researchers and informed readers, and it describes what studies have investigated rather than any outcome an individual should expect. BPC-157 is a research compound and is not characterized for human use here.
BPC-157 is a pentadecapeptide, meaning a peptide of fifteen amino acids, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a partial sequence of a larger protein, a body-protection compound, identified and isolated from human gastric juice. For this reason, it is often referred to as a stable gastric pentadecapeptide. The molecule does not occur in nature in this isolated fifteen-residue form, and the material used in studies is produced synthetically. The experimental work discussed below was carried out in cell cultures and animal models rather than in people.
There is no single agreed BPC-157 mechanism. Instead, several candidate pathways have emerged from in vitro and animal experiments, most of which relate to blood vessel formation and cell behavior at a wound site.
The most studied angiogenic pathway stems from a 2017 study by Hsieh and colleagues,[1] which combined a rat hind-limb model with cultured human vascular endothelial cells. In this study, the peptide was associated with increased expression and internalization of vascular endothelial growth factor receptor 2 (VEGFR2), as well as activation of the downstream VEGFR2-Akt-eNOS signaling axis. These findings are in vitro and animal-based, and the authors propose a mechanism rather than confirm an effect in humans.
A related set of studies by Chang and colleagues focused directly on connective tissue cells, particularly rat tendon fibroblasts. In 2014, the group reported[2] that the peptide increased growth hormone receptor expression in rat tendon fibroblasts at both the messenger RNA and protein levels in cell culture. In an earlier 2011 study,[3] the same group examined tendon fibroblast behavior and associated the peptide with faster cell outgrowth, improved cell survival under oxidative stress, and increased cell migration, effects the authors linked to the FAK-paxillin pathway. The nitric oxide system is also frequently discussed in the wider BPC-157 mechanism literature. All of these observations are cellular or animal results.
The strongest theme across BPC-157 research is soft-tissue repair in rodent injury models. The evidence separates usefully into in vitro work and in vivo animal studies.
The cell-based BPC-157 tendon studies described above offer a possible explanation for the animal results. Using tendon explants and isolated tendon fibroblasts from rats, Chang and colleagues[3] observed accelerated fibroblast outgrowth and migration in culture, along with greater cell survival under induced oxidative stress. These controlled laboratory findings in isolated cells do not, by themselves, demonstrate tissue healing in a living animal, let alone in a person.
A substantial part of the in vivo BPC-157 tissue-repair literature comes from linked studies by researchers at the University of Zagreb, many of which used rat surgical injury models. Early work by Staresinic and colleagues[4] in 2003 reported improved healing in a transected rat Achilles tendon model. Krivic and colleagues,[5] in a 2006 rat Achilles tendon model, reported improved tendon-to-bone healing across functional, biomechanical, and histological measures, and that the peptide reduced the healing impairment caused by a corticosteroid. Cerovecki and colleagues[6] extended this line of work to ligament tissue in 2010, describing improved medial collateral ligament healing over a ninety-day period in rats following surgical transection. Across these studies, the experimental approaches varied by model; this article does not describe administration regimens, which are study-specific and outside its scope.
This is the most important caveat in the field. Despite the volume of preclinical reports, there is very little human research on BPC-157 for tissue repair, and no randomized controlled trials have been published in this area. A 2025 systematic review by Vasireddi and colleagues,[7] examining the orthopedic literature, found that the evidence base remains overwhelmingly preclinical and noted that the compound has no approved indication. As of 2026, BPC-157 remains under active regulatory review rather than approved, and it is prohibited in competitive sport under the World Anti-Doping Agency rules. Readers should treat any extrapolation from animal data to people as unproven.
Several limitations shape how BPC-157 research should be interpreted. Much of the foundational in vivo work comes from a small number of affiliated laboratories, raising the usual questions about independent replication. Most animal studies are short-term and use acute surgical injury models that differ from chronic human conditions. Pharmacokinetic and long-term safety data in humans are sparse. Future directions discussed in the literature include independent replication of the angiogenic mechanism, better characterization of stability and metabolism, and properly controlled clinical studies, none of which currently exist at scale for tissue repair. Until such work is done, the honest summary is that the mechanism is plausible and the preclinical signal is consistent, but human evidence is essentially absent.
The BPC-157 research literature on tissue repair is substantial but lopsided: a coherent set of in vitro and rodent findings on angiogenesis and connective tissue cell behavior, against an almost complete absence of human trial data. For researchers, that combination defines both the interest and the caution the compound warrants. BPC-157 research peptide is intended for laboratory research use only, and the findings above describe what has been studied, not what any individual should expect.
BPC-157 is often discussed alongside TB-500 and GHK-Cu as part of a broader tissue-repair research class. For a comparison of this compound against the others studied in tissue repair, see Tissue Repair Peptides: Comparing BPC-157, TB-500 and GHK-Cu.
For the full range of research peptides available for laboratory use, see the Pure Peptides catalog.
BPC-157 is available for laboratory research from Pure Peptides. View Product →
References
Reviewed & approved for scientific accuracy
Dr. Martina Rossi
PhD — Scientific Contributor and Reviewer
Dr. Martina Rossi holds a PhD from Universite Grenoble Alpes, where her doctoral research examined the vascular functions of Bone Morphogenetic Proteins in knockout mouse models. Her published work spans cell and molecular biology, vascular biology, and gene therapy, with peer-reviewed contributions appearing in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. Dr. Rossi serves as Scientific Contributor and Reviewer for the Pure Peptides research content program, independently reviewing articles for scientific accuracy.
View team profile →
BPC-157, TB-500 and GHK-Cu in preclinical tissue repair research — angiogenesis, migration and matrix findings, evidence tiered. For research use only.
An evidence-led look at TB-500 research into Thymosin Beta-4 biology, covering the actin-binding domain, proposed mechanisms in cell migration and angiogenesis, and preclinical dermal and cardiac repair studies.
GHK-Cu is a copper-binding tripeptide studied for its effects on collagen synthesis and extracellular matrix biology, with newer preclinical research examining copper handling and neuroprotection in animal models.
